Table 2.
Clinical trials of Atovaquone in other cancers.
| Compound | NCT Identifier | Clinical Trial | Study | Doses of Atovaquone |
Route of Administration |
Other Treatment Modalities |
Study Assessment |
Outcome of the Study |
Reference |
|---|---|---|---|---|---|---|---|---|---|
| Atovaquone | NCT02628080 | Locally advanced NSCLC | Window of Opportunity study | 750 mg/5mL | Orally | - | Hypoxia modifier | Reduced tumour hypoxic volume | [38] |
| Atovaquone | NCT04648033 | NSCLC | Phase 1 (ARCADIAN) | 750 mg/5mL | Orally | Radiotherapy+ concurrent chemo | Radiosensitization | Ongoing: to assess maximum tolerated dose (MTD) | - |